mantle cell lymphoma

News

FDA starts priority review of BeOne's Venclexta rival

BeOne nears a possible FDA okay for sonrotoclax in mantle cell lymphoma, hoping to be the second BCL-2 inhibitor in the US after AbbVie's Venclexta.

News

NICE backs new drugs for Crohn's disease, lymphoma

Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.

News

Microscope view of nodular mantle cell lymphoma

AZ's Calquence gets first-line OK in mantle cell lymphoma

AstraZeneca's BTK inhibitor Calquence is the first drug in the class to be approved in the US for first-line treatment of mantle cell lymphoma.

News

AZ’s Calquence extends disease-free survival in MCL

AstraZeneca’s Calquence has been shown to improve progression-free survival in previously untreated mantle cell lymphoma (MCL), with an unprecedented trend towards improved overall survival

News

Lilly breaks new ground for BTK class with Jaypirca approval

Eli Lilly has picked up an FDA approval for its non-covalent BTK inhibitor Jaypirca in relapsed mantle cell lymphoma (MCL) patients who relapse after treatment with current drugs in the cla

News

Kite cues up first EMA okay for mantle cell lymphoma CAR-T

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

FDA starts priority review of BeOne's Venclexta rival

NICE backs new drugs for Crohn's disease, lymphoma

AZ's Calquence gets first-line OK in mantle cell lymphoma

AZ’s Calquence extends disease-free survival in MCL

Lilly breaks new ground for BTK class with Jaypirca approval

Kite cues up first EMA okay for mantle cell lymphoma CAR-T

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

mantle cell lymphoma

Editor's Picks